Skip to main content
← All trials
Ovarian CancerWomen's healthDrugPhase 3

What this study is

The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

What's being tested

  • INCB123667

    Intervention · DRUG

    Oral; tablet

  • Investigator's choice of chemotherapy

    Intervention · DRUG

    The investigator will select the chemotherapy in accordance with the protocol-defined requirements. The possible choices as defined by the protocol:

Study details

Official title
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Sponsor
Incyte Corporation
Conditions
Ovarian Cancer
Enrolling
466 people
Starts
2025-12-09
Est. completion
2029-05-14
Design
Open-label, randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗